We are live on ! Find out more
KAM

Krensavage Asset Management Portfolio holdings

AUM $256M
1-Year Est. Return 69.63%
This Fund
S&P 500
This Quarter Est. Return
+0.48%
1 Year Est. Return
+69.63%
3 Year Est. Return
+113.28%
5 Year Est. Return
+196.5%
10 Year Est. Return
+463.27%
AUM
$256M
AUM Growth
-$27.4M
Cap. Flow
-$24.1M
Cap. Flow %
-9.41%
Top 10 Hldgs %
86.89%
Holding
22
New
4
Increased
4
Reduced
4
Closed
2

Top Buys

Rank Stock Value
1
EMBC icon
Embecta
EMBC
+$7.66M
2
RARE icon
Ultragenyx Pharmaceutical
RARE
+$5.43M
3
ARDX icon
Ardelyx
ARDX
+$3.31M
4
BIIB icon
Biogen
BIIB
+$1.84M
5
INMD icon
InMode
INMD
+$1.72M

Top Sells

Rank Stock Value
1
AVDL
Avadel Pharmaceuticals
AVDL
+$18.4M
2
CAH icon
Cardinal Health
CAH
+$15.2M
3
BNTX icon
BioNTech
BNTX
+$4.11M
4
UTHR icon
United Therapeutics
UTHR
+$3.49M
5
EXEL icon
Exelixis
EXEL
+$3.35M

Sector Composition

Rank Sector Weight
1 Healthcare 100%

No holdings matched the selected filter criteria.

Similar funds

CIA
Corigliano Investment Advisers Raleigh, North Carolina $256M AUM 54.89% 1-Year Est. Return
2
2Xideas Kusnacht, Switzerland $255M AUM 0.46% 1-Year Est. Return
CIM
Caldwell Investment Management Toronto, Ontario, Canada $255M AUM 36.87% 1-Year Est. Return
LRIC
Long Road Investment Counsel Kalamazoo, Michigan $255M AUM 12.85% 1-Year Est. Return
GAMC
Garner Asset Management Corp Plano, Texas $255M AUM 22.93% 1-Year Est. Return
TIA
Tiemann Investment Advisors Menlo Park, California $255M AUM 21.35% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return
PHAM
Palisades Hudson Asset Management Fort Lauderdale, Florida $257M AUM 21.62% 1-Year Est. Return

Krensavage Asset Management's Q1 2026 Portfolio in Review

As of Q1 2026, Krensavage Asset Management held 22 positions worth $256M, down 9.7% from $283M the previous quarter. Its ten largest holdings account for 87% of the portfolio.

Krensavage Asset Management withdrew a net $24.1M in Q1 2026, closing 2 positions and reducing 4 holdings. Its most notable exit was Avadel Pharmaceuticals, an estimated $18.4M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, Krensavage Asset Management opened a new position in Embecta worth $6.5M.

  • Krensavage Asset Management's largest Q1 2026 buy was Embecta: 735,340 shares worth $6.5M.
  • Krensavage Asset Management added most to Ultragenyx Pharmaceutical in Q1 2026, an estimated $5.43M increase.
  • Krensavage Asset Management's biggest Q1 2026 reduction was BioNTech, cutting an estimated $4.11M.
  • Krensavage Asset Management fully exited Avadel Pharmaceuticals in Q1 2026, selling an estimated $18.4M.
  • Krensavage Asset Management's ten largest holdings make up 87% of its $256M portfolio in Q1 2026.
  • Krensavage Asset Management opened 4 new positions and closed 2 in Q1 2026.
  • Krensavage Asset Management's portfolio value fell 9.7% quarter-over-quarter to $256M.

Based on Krensavage Asset Management's 13F filing for Q1 2026, filed 15 May 2026.